Group 1 - The company, Nanjing Pharmaceutical Co., Ltd., has announced the issuance of its first medium-term note for 2023, with a total issuance amount of 100,000 million yuan [1] - The bond, named "23 Nanjing Pharmaceutical MTN001," has an interest rate of 3.1% and a maturity date set for June 20, 2025 [1] - The main underwriters for this bond issuance are Bank of Communications Co., Ltd. and Industrial Bank Co., Ltd. [1] Group 2 - The bond's interest and principal repayment will be managed by the China Interbank Market Clearing House Co., Ltd., which will transfer funds to bondholders on the specified payment date [1] - In case the payment date falls on a public holiday, the payment will be postponed accordingly [1] - The company and the clearing house will not be liable for any losses incurred due to delays in fund transfers if bondholders fail to notify changes in their payment account in a timely manner [1]

Group 1 - The announcement pertains to the exercise of investor put options and the issuer's adjustment of the coupon rate for the 2023 first phase medium-term notes issued by Nanjing Pharmaceutical Co., Ltd [1][2] - The bond has an issuance amount of 1 billion yuan, with a coupon rate of 3.10% and a maturity period of 2+1 years, starting from June 20, 2023 [2] - The investor put option can be exercised from May 22, 2025, to May 28, 2025, with a repurchase price of 100 yuan per 100 yuan face value, and the exercise date is June 20, 2025 [2] Group 2 - The issuer has the option to adjust the coupon rate, which is currently set at 3.10%, and can be reduced by 150 basis points to a new rate of 1.60%, effective from June 20, 2025 [2] - The main underwriters for the bond issuance are Bank of Communications Co., Ltd. and Industrial Bank Co., Ltd. [2] - The announcement includes contact information for the issuer and the management institution, ensuring transparency and accessibility for investors [2][3]